Status:
RECRUITING
China Early Esophageal Cancer Cohort
Lead Sponsor:
Changhai Hospital
Collaborating Sponsors:
Lianshui People's Hospital
The second affiliated hospital of Xuzhou medical university
Conditions:
Early Esophageal Cancer
Eligibility:
All Genders
15-85 years
Brief Summary
With the development of endoscopy, more and more patients with superficial esophageal squamous cell carcinoma (ESCC) receive endoscopic resection rather than traditional surgery. However, there is sti...
Eligibility Criteria
Inclusion
- Men and women, aged 18-85.
- ESD was performed for early (superficial) esophageal squamous cell carcinoma, and the indication was in line with domestic and foreign guidelines.
- The pathological stage after ESD was pT1a/pT1b.
- The effective follow-up time after ESD was ≥3 years, or recurrence or LNM occurred during the follow-up period.
Exclusion
- Esophageal chemoradiotherapy or esophageal surgery were performed before ESD.
- There is a history of carcinoma, early carcinoma, adenoma and other benign and malignant tumors of stomach and duodenum.
- Pathological data after ESD were incomplete.
- Combined with malignant tumors of other organs.
- Fragmented endoscopic mucosal resection (EMR), multi-loop mucosal resection (MBM) and other endoscopic non-monolithic resection techniques were used.
- New squamous cell carcinoma in other parts of esophagus during follow-up (metachronous carcinoma).
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06515964
Start Date
October 1 2022
End Date
October 1 2025
Last Update
July 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433